ATE348175T1 - Method eder intrazellularen bindung von zielgerichteten molekülen - Google Patents

Method eder intrazellularen bindung von zielgerichteten molekülen

Info

Publication number
ATE348175T1
ATE348175T1 AT93918231T AT93918231T ATE348175T1 AT E348175 T1 ATE348175 T1 AT E348175T1 AT 93918231 T AT93918231 T AT 93918231T AT 93918231 T AT93918231 T AT 93918231T AT E348175 T1 ATE348175 T1 AT E348175T1
Authority
AT
Austria
Prior art keywords
target
antibody
binding
targeted molecules
intracellular binding
Prior art date
Application number
AT93918231T
Other languages
English (en)
Inventor
Wayne A Marasco
William A Haseltine
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE348175T1 publication Critical patent/ATE348175T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/81—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the endoplasmatic reticulum [ER] or the Golgi apparatus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93918231T 1992-07-17 1993-07-16 Method eder intrazellularen bindung von zielgerichteten molekülen ATE348175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91693992A 1992-07-17 1992-07-17
US4527493A 1993-03-31 1993-03-31

Publications (1)

Publication Number Publication Date
ATE348175T1 true ATE348175T1 (de) 2007-01-15

Family

ID=26722587

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918231T ATE348175T1 (de) 1992-07-17 1993-07-16 Method eder intrazellularen bindung von zielgerichteten molekülen

Country Status (10)

Country Link
US (4) US6004940A (de)
EP (1) EP0651805B1 (de)
CN (1) CN1084216A (de)
AT (1) ATE348175T1 (de)
AU (1) AU687010B2 (de)
CA (1) CA2137558A1 (de)
DE (1) DE69334095T2 (de)
MX (1) MX9304363A (de)
PT (1) PT651805E (de)
WO (1) WO1994002610A1 (de)

Families Citing this family (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687010B2 (en) * 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
IL107026A0 (en) * 1992-09-16 1993-12-28 Univ Tennessee Res Corp Antigen of hybrid m protein and carrier for group a streptococcal vaccine
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
WO1995003832A1 (en) * 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
EP0745134A1 (de) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nukleinsäureverabreichungs-system, verfahren zur dessen synthese und seine verwendungen
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
AU733719B2 (en) 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6395530B1 (en) 1996-12-06 2002-05-28 Aventis Pharmaceuticals Inc. LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
EP1015616A2 (de) * 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Intrakörpermediierte kontrolle von immunreaktionen
US6077676A (en) * 1997-12-18 2000-06-20 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
EP1049767B1 (de) 1998-01-08 2005-08-17 Aventis Pharmaceuticals Inc. Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
WO2001021800A1 (en) * 1999-09-20 2001-03-29 Aberdeen University Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus)
AU2841101A (en) * 1999-12-08 2001-06-18 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cellsby hiv-1
US7078486B2 (en) 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
EP1254169B1 (de) 1999-12-30 2007-05-09 President And Fellows of Harvard College Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
US6291652B1 (en) 2000-01-07 2001-09-18 The Regents Of The University Of California Antibodies specific for proteins having polyglutamine expansions
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
PT1290023E (pt) 2000-03-31 2011-01-05 Aventis Pharma Inc Factor indutor do factor nuclear kb
WO2001082901A1 (en) * 2000-04-28 2001-11-08 Zengen, Inc. New antibodies to biological membranes
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
ATE489462T1 (de) * 2002-04-25 2010-12-15 Toagosei Co Ltd Antimikrobielles polypeptid und nutzung davon
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2004065416A2 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
EP2363493B1 (de) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Neue Einführungsstellen in Pocken-Vektoren
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US7674771B2 (en) 2003-10-29 2010-03-09 Toagosei Co., Ltd Antimicrobial peptides and utilization of the same
EP1737971B1 (de) * 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JP4507080B2 (ja) 2004-07-30 2010-07-21 東亞合成株式会社 抗菌ペプチド及びその利用
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060147997A1 (en) * 2004-11-30 2006-07-06 Virosys Pharmaceuticals, Inc. PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
EP1973951A2 (de) * 2005-12-02 2008-10-01 Genentech, Inc. Bindende polypeptide mit eingeschränkten diversitätssequenzen
CA2633887C (en) 2005-12-15 2015-12-22 Genentech, Inc. Methods and compositions for targeting polyubiquitin
GB0605584D0 (en) * 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
TW200812616A (en) * 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
EP2041574B1 (de) 2006-07-14 2016-11-16 The Regents of The University of California Krebsbiomarker und anwendungsverfahren dafür
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (de) 2007-09-14 2020-04-15 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
CN102224254A (zh) 2008-09-23 2011-10-19 哈佛大学校长及研究员协会 Sirt4及其用途
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
JP5851838B2 (ja) 2008-10-22 2016-02-03 ジェネンテック， インコーポレイテッド 軸索変性の調節
WO2010048423A1 (en) 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Levetiracetam immunoassays
CA2740192C (en) 2008-12-01 2019-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
DK2414542T3 (da) 2009-03-30 2017-11-27 Tel Hashomer Medical Res Infrastructure & Services Ltd Fremgangsmåder til forudsigelse af klinisk forløb for og behandling af multipel sklerose
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
EP3011970A3 (de) 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation der axondegeneration
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
EP3309176B1 (de) 2009-12-14 2025-10-01 Ablynx N.V. Variable einzeldomänen-antikörper gegen ox40l, konstrukte und ihre therapeutische verwendung
EP2516465B1 (de) 2009-12-23 2016-05-18 F.Hoffmann-La Roche Ag Anti-bv8 antikörper und deren verwendungen
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011085178A1 (en) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
GB201004292D0 (en) * 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
RU2012148398A (ru) 2010-04-18 2014-05-27 Иеда Рисеч Энд Девелопмент Ко. Лтд. МОЛЕКУЛЫ И СПОСОБЫ ПРИМЕНЕНИЯ МОЛЕКУЛ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ, АССОЦИИРОВАННЫХ С ErbB/ErbB ЛИГАНДАМИ
US12571798B2 (en) 2010-04-27 2026-03-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
EP2571901B1 (de) 2010-05-20 2019-01-02 Ablynx N.V. Biologische stoffe im zusammenhang mit her3
GB201011971D0 (en) 2010-07-15 2010-09-01 Olink Ab Methods and product
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
US10669569B2 (en) 2010-10-15 2020-06-02 Navinci Diagnostics Ab Dynamic range methods
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
EP2466310A1 (de) 2010-12-17 2012-06-20 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Mittel und Verfahren für den Nachweis von mehrstrangigen Brüchen
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
EP2673297A2 (de) 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalente und multivalente multispezifische komplexe und verwendungen davon
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
GB201107863D0 (en) 2011-05-11 2011-06-22 Olink Ab Method and product
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
EP2723772A1 (de) 2011-06-23 2014-04-30 Ablynx N.V. Gegen ige gerichtete variable immunglobulin-einzeldomänen
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
GB201201547D0 (en) 2012-01-30 2012-03-14 Olink Ab Method and product
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2855698A4 (de) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc Abzielung auf den glutamin-zu-pyruvat-signalweg zur behandlung von mit dem kras-onkogen assoziierten krebs
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
EP2879710B1 (de) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Medizinische verwendungen von immunzellenaktivierungsmodulierenden substanzen und entsprechende screeningverfahren
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
CN109535259A (zh) * 2012-12-05 2019-03-29 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2945942B1 (de) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazol-immunoassays
EP2956444B1 (de) 2013-02-13 2018-05-30 ARK Diagnostics, Inc. Posaconazol-immunoassays
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
CA2901513C (en) 2013-03-12 2020-12-29 Ventana Medical Systems, Inc. Proximity assay for in situ detection of targets
WO2014139979A1 (en) 2013-03-12 2014-09-18 Ventana Medical Systems, Inc. Quantum dot in situ hybridization
WO2014151763A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
EP3293275B1 (de) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
CN105636984A (zh) 2013-06-13 2016-06-01 法斯特弗沃德制药有限公司 用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
AU2014296288B2 (en) 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
CN105658230B (zh) 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
ES2694857T3 (es) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
WO2015153639A1 (en) 2014-03-31 2015-10-08 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3169343B1 (de) 2014-07-15 2020-03-25 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Isolierte polypeptide von cd44 und verwendungen davon
WO2016016341A1 (en) * 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
US20160115247A1 (en) * 2014-10-23 2016-04-28 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
SI3215527T1 (sl) 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
WO2016090323A1 (en) 2014-12-05 2016-06-09 Prelude, Inc. Dcis recurrence and invasive breast cancer
ES3015000T3 (en) 2014-12-08 2025-04-28 Dana Farber Cancer Inst Inc Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
AU2016209056B2 (en) 2015-01-24 2021-01-28 Academia Sinica Cancer markers and methods of use thereof
WO2016123593A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3253784B1 (de) 2015-02-04 2020-05-06 Genentech, Inc. Smoothened-mutant und verfahren zur verwendung davon
EP3265074B1 (de) 2015-03-03 2020-08-12 ARK Diagnostics, Inc. Pregabalinimmunoassays
EP3268025B1 (de) 2015-03-10 2020-05-06 University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3294280A1 (de) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrinhemmer zur behandlung von krebs
CN114920848B (zh) 2015-05-13 2024-10-11 埃博灵克斯股份有限公司 基于cd3反应性的t细胞募集多肽
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
EP3403091B1 (de) 2016-01-11 2021-12-22 Technion Research & Development Foundation Limited Verfahren zur bestimmung der prognose von sepsis und behandlung davon
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP3426693A4 (de) 2016-03-08 2019-11-13 Academia Sinica Verfahren zur modularen synthese von n-glykanen und anordnungen davon
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017175228A1 (en) 2016-04-06 2017-10-12 Technion Research & Development Foundation Limited Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN106178163B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物细胞免疫治疗仪
CN106267409B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病生物治疗反应器
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
ES3033182T3 (en) 2016-09-20 2025-07-31 Dana Farber Cancer Inst Inc Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
WO2018216011A1 (en) 2017-05-23 2018-11-29 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
CA3080109A1 (en) * 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
WO2019168897A2 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US20210147487A1 (en) * 2018-04-04 2021-05-20 The University Of North Carolina At Chapel Hill Methods and compositions for engineered assembly activating proteins (eaaps)
US20220125891A1 (en) 2018-06-06 2022-04-28 Osaka University Method for treating and/or preventing regnase-1-related disease
WO2019238944A1 (en) 2018-06-15 2019-12-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US20220187301A1 (en) 2018-09-14 2022-06-16 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
US12240916B2 (en) 2018-09-21 2025-03-04 National Research Council Of Canada Intrabodies for reducing FUT8 activity
CA3115077A1 (en) 2018-10-09 2020-04-16 Ibex Biosciences, Llc Antibodies directed to filamin-a and therapeutic uses thereof
US20220042993A1 (en) * 2018-11-12 2022-02-10 Andrew L. Mason Betaretrovirus epitopes and related methods of use
JP2022513082A (ja) 2018-11-19 2022-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
EP3962529A4 (de) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4041392A1 (de) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antikörper gegen den poliovirus-rezeptor (pvr) und verwendungen davon
WO2021149040A1 (en) 2020-01-22 2021-07-29 Ramot At Tel-Aviv University Ltd. Anti-ide antibodies and uses of same
EP4093513A4 (de) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Verwendung von biomarkern zur verbesserung der immuntherapie
EP4096647A1 (de) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Behandlung einer akuten lebererkrankung mit tlr-mik-inhibitoren
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
WO2022173932A1 (en) 2021-02-11 2022-08-18 Dana-Farber Cancer Institute, Inc. Methods of treating cancers using sting agonists
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
WO2022187374A1 (en) 2021-03-02 2022-09-09 Dana-Farber Cancer Institute, Inc. Methods of treating red blood cell disorders
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP4433592A1 (de) 2021-11-18 2024-09-25 Circularis Biotechnologies, Inc. Zusammensetzungen und verfahren zur herstellung von zirkulären nukleinsäuremolekülen
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
EP4605077A1 (de) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Gegen den melanocortin-4-rezeptor gerichtete aminosäuresequenzen und polypeptide damit zur behandlung von mc4r-bedingten erkrankungen und störungen
JPWO2024143442A1 (de) 2022-12-27 2024-07-04
EP4655590A1 (de) 2023-01-27 2025-12-03 Biomerieux Modifizierter immunmolekulartest zum schnelleren nachweis von biomarkern
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
WO2025111398A1 (en) 2023-11-20 2025-05-30 Alamar Biosciences, Inc. Reduction of non-cognate signal in multiplex proximity ligation assays
WO2025111396A1 (en) 2023-11-20 2025-05-30 Alamar Biosciences, Inc. Molecular barcode set and use thereof in multiplex proximity detection assays
WO2025111397A1 (en) 2023-11-20 2025-05-30 Alamar Biosciences, Inc. Use of autoinhibition standard curves in proximity assays
WO2025207946A1 (en) 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556197A4 (en) * 1990-09-25 1994-05-18 Univ Connecticut Prolonging expression of polynucleotides introduced into a cell
WO1993007286A1 (en) * 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
EP0618970A1 (de) * 1991-12-10 1994-10-12 Dana Farber Cancer Institute Reaktive neutralisierende humane anti-gp120 rekombinante antikörper, entsprechend kodierende dna und ihre verwendung
AU687010B2 (en) * 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules

Also Published As

Publication number Publication date
MX9304363A (es) 1994-02-28
AU4775393A (en) 1994-02-14
DE69334095D1 (de) 2007-01-25
AU687010B2 (en) 1998-02-19
CA2137558A1 (en) 1994-02-03
US6329173B1 (en) 2001-12-11
US6004940A (en) 1999-12-21
EP0651805A1 (de) 1995-05-10
PT651805E (pt) 2007-02-28
DE69334095T2 (de) 2007-04-12
EP0651805B1 (de) 2006-12-13
CN1084216A (zh) 1994-03-23
WO1994002610A1 (en) 1994-02-03
US6072036A (en) 2000-06-06
US5965371A (en) 1999-10-12

Similar Documents

Publication Publication Date Title
ATE348175T1 (de) Method eder intrazellularen bindung von zielgerichteten molekülen
EP0728215A4 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS -g(b)-AMYLOID-PEPTID
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
PT2305715T (pt) Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
ATE470712T1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EE05496B1 (et) Antikeha, mis seob osteoprotegeriini siduvat valku
HUS1400027I1 (hu) OBM elleni antitestek
EP0930366A3 (de) Bindungsdomänen des Serrate-proteins
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE69222956D1 (de) Kleinste erkennungseinheit eines pem-mucin-"tandem repeat"-spezifischen monoklonalen antikoerpers
BR9407512A (pt) Sequência de ácidos nucléicos vírus recombinante defectivo vetor notadamente virale composição farmaceutica e utilização de uma sequencia de ácidos nucléicos
KR890010203A (ko) 유전공학을 이용한 항체의 제조방법
ATE332914T1 (de) Mimotope und antimimotope des menschlichen plättchen-glykoproteins ib/ix
IL127297A0 (en) Spruce budworm antifreeze proteins genes and methods of using same
NO944887L (no) Monoklonale antistoffer mot glykoprotein
DE69535789D1 (de) Il-2r-assoziiertes polypeptid und dafür kodierende dna-molekülen
NO962084L (no) DNA sekvens som koder for en BMP reseptor
DE69637154D1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
WO2001016170A3 (en) Card proteins involved in cell death regulation
DK0629238T3 (da) Autotaxin:Motilitetsstimulerende protein, som er nyttigt til cancerdiagnose og terapi
BR9611851A (pt) Molécula de ácido nucléico isolada e purificada, vetor de experessão recombinatória, célula hospedeira contendo um vetor de expressão recombina tório, proteìnas tbpa e tbpb isolada e purificadas, método para preparar uma protéina tbpa e tbpb, anti-corpo policlÈnico ou monoclÈnico, e vacinas assim obtidas
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0651805

Country of ref document: EP

REN Ceased due to non-payment of the annual fee